Akari Therapeutics (AKTX) news
Recent news
Akari Therapeutics enters strategic research collaboration with Whitehawk Therapeutics
AInvest Wire · Jul 21, 2026Akari Therapeutics PLC: Maxim Group raises to buy from hold
Maxim Group has upgraded its rating for Akari Therapeutics PLC (AKTX), moving from "Hold" to "Buy," reflecting a positive shift in the firm's outlook for the biopharmaceutical company. The decision follows recent developments in Akari's clinical pipeline and strategic initiatives aimed at advancing…
AInvest Wire · Jul 20, 2026Akari Therapeutics - prospectus relates to resale of up to 6 mln ADSs representing 480 bln ordinary shares by the selling shareholders - SEC filing
AInvest Wire · Jul 2, 2026Akari Therapeutics - files to offer up to 2.5 mln ADSs via White Lion Capital - SEC filing
Akari Therapeutics, Plc (NASDAQ: AKTX) has entered into an Ordinary Share Purchase Agreement with White Lion Capital, LLC, granting the company the right to sell up to $25 million in newly issued ordinary shares, which may be exchanged for American Depositary Shares (ADSs), each representing 2,000…
AInvest Wire · Jun 26, 2026Akari Therapeutics reports $5.5M placement offering
AInvest Wire · May 21, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.